Study demonstrates that cell-specific delivery of sugar- and charge-modified albumins in fibrotic livers is possible by coupling drugs to lactose and mannose
Bioavailability of 5-iodo -deoxyuridine -monophosphate to the parenchymal liver cell is dramatically enhanced as a result of the conjugation of the antiviral drugs to lactosylated poly-L-lysine
Permanent magnets and calcein as a fluorescent marker
Dextran magnetite (DM)-incorporated thermosensitive liposomes would be useful in future cancer treatment by magnetic targeting combined with drug release in response to hyperthermia
Tyr3-octreotide (TOC), a somatostatin analogue shows enhanced therapeutic efficacy due to the liver-targeting effect when coupled with -palmitoyl cysteinyl moiety.
SG liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for asialoglycoprotein receptor (ASGP-R) on hepatocytes
The modified proteins could target high doses of chemotherapeutic drugs (CDDP and 5-fluorouridine) to the liver through biotinyl dextran-derived carriers
5-Fluoro 29-deoxyuridine conjugated with lactosaminated poly-L-lysine
Lactose
Poly-L-lysine-5-fluoro--deoxyuridine enters into HepG2 cells through the asialoglycoprotein receptor and, after intracellular penetration, releases the drug in a pharmacologically active form